Hypoxia and VEGF secretion from cancer epithelial cells seem to be themain mechanism driving ITH and TME changes in heterogenous cancers, providing asupplementary rationale for the use of anti-VEGF and anti-angiogenic drugs in thetreatment of primary liver cancer.58 Here, VEGFA is linked to liver cancer.